Although Biovail will begin promotimg the 3.6mg dosage of the drug, AstraZeneca will continue to manufacture and supply all quantities of Zoladex.
Endometriosis is a painful, chronic disease that occurs when tissue similar to that which lines the uterus (tissue called the endometrium) is found in the area surrounding the uterus. This misplaced tissue has no way to leave the body during menstruation and results in internal bleeding, breakdown of the blood and tissue from the lesions, and inflammation – and can cause pain, infertility, scar-tissue formation, adhesions, and bowel problems.
Biovail CEO Dr Douglas Squires said the opportunity to promote the 3.6mg formulation of Zoladex will further enable the company to build its portfolio of products to promote to the women’s health-care market.
“Biovail will leverage its expertise and relationships with women’s health-care practitioners in the US to proactively position the therapeutic benefits of Zoladex 3.6mg as an important treatment to females who suffer from endometriosis,” said Dr Squires.